Universidad Complutense de Madrid
ucm.esLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
199
Active
50
Phase 3
4
Total enrollment
15,697
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sodium hyaluronate 0.01% and Sh-Oligopeptide-85 SP Mouthwash | — | — | — | — | — | 1 | |
| Nerve block with Lidocain | — | — | — | — | — | 1 | |
| Application of Enamel Matrix Derivatives | — | — | — | — | — | 1 | |
| Theravex Bioactive Solutions | — | — | — | — | — | 1 |
Next readouts
- 2026-07
- 2026-12-17
- 2027-07-06
- 2028-11-01
Top conditions
- Periodontitis10
- Low Back Pain9
- Diabetic Foot7
- Diabetic Foot Ulcer7
- Peri-Implantitis6
- Depression5
- Dental Materials4
- Peri-implant Mucositis4
Frequently asked questions about Universidad Complutense de Madrid
- How many clinical trials does Universidad Complutense de Madrid have on ClinicalTrials.gov?
- Universidad Complutense de Madrid is listed as the lead sponsor on 199 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidad Complutense de Madrid's trials are in Phase 3?
- 4 of Universidad Complutense de Madrid's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Universidad Complutense de Madrid focus on?
- Universidad Complutense de Madrid's most-studied conditions on ClinicalTrials.gov are Periodontitis, Low Back Pain, Diabetic Foot, Diabetic Foot Ulcer, Peri-Implantitis.
- When are Universidad Complutense de Madrid's next clinical trial readouts?
- Universidad Complutense de Madrid has 4 upcoming primary-completion readouts tracked here; the soonest is “Periodontal Regeneration at the Distal Site of Second Molars After the Extraction of Lower Included Third Molars”, expected around 2026-07.